Siddhartha Mitra
Concepts (333)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Brain Neoplasms | 18 | 2023 | 980 | 2.520 |
Why?
| Glioblastoma | 11 | 2023 | 253 | 2.340 |
Why?
| Glioma | 6 | 2022 | 296 | 1.730 |
Why?
| Medulloblastoma | 7 | 2023 | 172 | 1.450 |
Why?
| Cerebellar Neoplasms | 4 | 2023 | 131 | 1.220 |
Why?
| CD47 Antigen | 7 | 2019 | 21 | 1.020 |
Why?
| Phagocytosis | 7 | 2023 | 355 | 0.750 |
Why?
| Microglia | 2 | 2020 | 203 | 0.750 |
Why?
| Myeloid-Derived Suppressor Cells | 1 | 2021 | 56 | 0.710 |
Why?
| Neurons | 8 | 2015 | 1298 | 0.710 |
Why?
| Drug Resistance, Neoplasm | 2 | 2021 | 638 | 0.690 |
Why?
| Tumor Microenvironment | 3 | 2023 | 431 | 0.650 |
Why?
| Neoplastic Stem Cells | 6 | 2022 | 331 | 0.640 |
Why?
| Leukemia, Lymphocytic, Chronic, B-Cell | 4 | 2020 | 58 | 0.580 |
Why?
| Neural Stem Cells | 2 | 2015 | 115 | 0.570 |
Why?
| Nerve Tissue Proteins | 7 | 2015 | 535 | 0.540 |
Why?
| Nuclear Proteins | 6 | 2018 | 594 | 0.540 |
Why?
| Macrophages | 7 | 2023 | 1284 | 0.520 |
Why?
| Immunotherapy | 6 | 2021 | 479 | 0.510 |
Why?
| Meningomyelocele | 1 | 2015 | 57 | 0.490 |
Why?
| Huntington Disease | 3 | 2010 | 38 | 0.460 |
Why?
| Oligodendroglia | 1 | 2015 | 149 | 0.450 |
Why?
| Signal Transduction | 9 | 2019 | 4541 | 0.430 |
Why?
| Inclusion Bodies | 4 | 2011 | 24 | 0.430 |
Why?
| Oncogene Protein pp60(v-src) | 1 | 2012 | 5 | 0.420 |
Why?
| Connexin 43 | 1 | 2012 | 23 | 0.420 |
Why?
| Ion Channel Gating | 1 | 2012 | 83 | 0.410 |
Why?
| Gap Junctions | 1 | 2012 | 58 | 0.400 |
Why?
| ErbB Receptors | 6 | 2013 | 557 | 0.400 |
Why?
| Oocytes | 1 | 2012 | 171 | 0.390 |
Why?
| Receptors, Immunologic | 3 | 2019 | 203 | 0.370 |
Why?
| Rhabdoid Tumor | 2 | 2022 | 79 | 0.350 |
Why?
| Animals | 36 | 2023 | 32102 | 0.350 |
Why?
| Cell Line, Tumor | 15 | 2022 | 2751 | 0.350 |
Why?
| Ependymoma | 2 | 2023 | 158 | 0.340 |
Why?
| Immunization, Passive | 1 | 2010 | 80 | 0.340 |
Why?
| Cell Proliferation | 10 | 2022 | 2194 | 0.340 |
Why?
| B7 Antigens | 2 | 2020 | 9 | 0.340 |
Why?
| Imidazoles | 3 | 2020 | 217 | 0.330 |
Why?
| Ubiquitin | 1 | 2008 | 64 | 0.310 |
Why?
| Mice | 22 | 2023 | 15052 | 0.310 |
Why?
| Proteasome Endopeptidase Complex | 1 | 2008 | 136 | 0.310 |
Why?
| Receptors, Notch | 2 | 2022 | 85 | 0.300 |
Why?
| Immunotherapy, Adoptive | 2 | 2020 | 194 | 0.290 |
Why?
| Pyrimidines | 3 | 2020 | 376 | 0.290 |
Why?
| Humans | 48 | 2023 | 115613 | 0.280 |
Why?
| Xenograft Model Antitumor Assays | 9 | 2020 | 704 | 0.280 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 1361 | 0.270 |
Why?
| Gene Expression Regulation | 4 | 2013 | 2353 | 0.260 |
Why?
| Antibodies | 3 | 2017 | 374 | 0.260 |
Why?
| Cells, Cultured | 8 | 2020 | 3914 | 0.260 |
Why?
| Mice, Inbred NOD | 8 | 2022 | 560 | 0.250 |
Why?
| Antineoplastic Agents | 5 | 2022 | 1893 | 0.250 |
Why?
| Purines | 4 | 2020 | 159 | 0.250 |
Why?
| Antigens, Differentiation | 2 | 2017 | 79 | 0.240 |
Why?
| Cancer Vaccines | 2 | 2020 | 137 | 0.240 |
Why?
| Quinazolinones | 3 | 2020 | 19 | 0.240 |
Why?
| Neoplasms, Experimental | 4 | 2019 | 153 | 0.240 |
Why?
| Hedgehog Proteins | 3 | 2022 | 172 | 0.240 |
Why?
| Teratoma | 2 | 2022 | 92 | 0.210 |
Why?
| Mice, SCID | 7 | 2020 | 321 | 0.210 |
Why?
| Infratentorial Neoplasms | 1 | 2023 | 45 | 0.210 |
Why?
| Neoplastic Cells, Circulating | 2 | 2020 | 59 | 0.210 |
Why?
| Protein-Tyrosine Kinases | 2 | 2017 | 396 | 0.210 |
Why?
| Electron Transport Complex I | 1 | 2022 | 33 | 0.200 |
Why?
| Antibodies, Monoclonal | 4 | 2019 | 1265 | 0.200 |
Why?
| Proto-Oncogene Proteins c-mdm2 | 1 | 2022 | 57 | 0.190 |
Why?
| Polycomb Repressive Complex 1 | 2 | 2018 | 40 | 0.190 |
Why?
| Lymphocytes, Tumor-Infiltrating | 1 | 2022 | 111 | 0.190 |
Why?
| Radiation Tolerance | 1 | 2022 | 92 | 0.190 |
Why?
| Histone Deacetylase Inhibitors | 1 | 2023 | 199 | 0.190 |
Why?
| Rituximab | 2 | 2019 | 149 | 0.180 |
Why?
| Brain Stem Neoplasms | 2 | 2012 | 86 | 0.180 |
Why?
| Neoplasm Grading | 1 | 2021 | 244 | 0.180 |
Why?
| Meningeal Neoplasms | 2 | 2018 | 88 | 0.170 |
Why?
| Lymphoma, Mantle-Cell | 1 | 2019 | 18 | 0.170 |
Why?
| Gene Expression Regulation, Neoplastic | 3 | 2022 | 1147 | 0.170 |
Why?
| Cell Tracking | 1 | 2019 | 13 | 0.170 |
Why?
| Antineoplastic Agents, Alkylating | 1 | 2019 | 68 | 0.170 |
Why?
| Salvage Therapy | 1 | 2020 | 128 | 0.160 |
Why?
| NF-kappa B | 1 | 2023 | 639 | 0.160 |
Why?
| Single-Cell Analysis | 1 | 2020 | 188 | 0.160 |
Why?
| Neoplasms | 3 | 2021 | 2118 | 0.160 |
Why?
| Peptides | 4 | 2013 | 864 | 0.160 |
Why?
| Corpus Striatum | 2 | 2010 | 124 | 0.160 |
Why?
| Neoplasm Recurrence, Local | 2 | 2022 | 863 | 0.160 |
Why?
| Tomography, Optical Coherence | 1 | 2019 | 128 | 0.160 |
Why?
| Receptor, Notch1 | 1 | 2018 | 59 | 0.160 |
Why?
| Osteosarcoma | 1 | 2019 | 66 | 0.150 |
Why?
| Myeloid Cells | 1 | 2019 | 127 | 0.150 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2022 | 449 | 0.150 |
Why?
| Small Molecule Libraries | 1 | 2018 | 81 | 0.150 |
Why?
| Antigens, Neoplasm | 1 | 2019 | 223 | 0.140 |
Why?
| Cytoreduction Surgical Procedures | 1 | 2017 | 40 | 0.140 |
Why?
| Azepines | 2 | 2014 | 74 | 0.140 |
Why?
| Contrast Media | 1 | 2019 | 362 | 0.140 |
Why?
| Prazosin | 1 | 2016 | 26 | 0.140 |
Why?
| Oncogene Protein v-akt | 1 | 2016 | 26 | 0.140 |
Why?
| Drug Repositioning | 1 | 2016 | 13 | 0.140 |
Why?
| Transcription Factors | 2 | 2014 | 1528 | 0.130 |
Why?
| Protein Kinase Inhibitors | 2 | 2019 | 790 | 0.130 |
Why?
| Triazoles | 2 | 2014 | 132 | 0.130 |
Why?
| Imaging, Three-Dimensional | 1 | 2019 | 495 | 0.130 |
Why?
| Neoplasm Proteins | 1 | 2019 | 385 | 0.130 |
Why?
| Protein Kinase C-delta | 1 | 2016 | 70 | 0.130 |
Why?
| Survival Analysis | 5 | 2017 | 1219 | 0.130 |
Why?
| Calreticulin | 1 | 2015 | 24 | 0.120 |
Why?
| Cell Adhesion Molecules, Neuronal | 1 | 2015 | 35 | 0.120 |
Why?
| Nanoparticles | 1 | 2019 | 316 | 0.120 |
Why?
| Casein Kinase II | 1 | 2014 | 21 | 0.120 |
Why?
| Huntingtin Protein | 3 | 2010 | 10 | 0.120 |
Why?
| T-Lymphocytes | 2 | 2020 | 1756 | 0.120 |
Why?
| Structure-Activity Relationship | 2 | 2012 | 511 | 0.120 |
Why?
| Disease Models, Animal | 6 | 2022 | 3580 | 0.120 |
Why?
| Epigenesis, Genetic | 2 | 2018 | 526 | 0.120 |
Why?
| Molecular Targeted Therapy | 2 | 2013 | 348 | 0.120 |
Why?
| Cell Death | 3 | 2011 | 326 | 0.120 |
Why?
| Toll-Like Receptors | 1 | 2015 | 166 | 0.110 |
Why?
| Antibody Specificity | 2 | 2011 | 176 | 0.110 |
Why?
| Cell Differentiation | 3 | 2016 | 1700 | 0.110 |
Why?
| Mitochondria | 2 | 2022 | 750 | 0.110 |
Why?
| Ubiquitin Thiolesterase | 1 | 2013 | 37 | 0.110 |
Why?
| Proto-Oncogene Proteins c-myc | 1 | 2013 | 114 | 0.110 |
Why?
| Multiprotein Complexes | 1 | 2013 | 145 | 0.100 |
Why?
| Inflammation | 1 | 2023 | 2500 | 0.100 |
Why?
| Xenopus laevis | 1 | 2012 | 118 | 0.100 |
Why?
| Quality of Life | 1 | 2023 | 2387 | 0.100 |
Why?
| Protein Kinases | 1 | 2013 | 306 | 0.100 |
Why?
| Brain | 2 | 2020 | 2373 | 0.100 |
Why?
| Prognosis | 5 | 2020 | 3339 | 0.100 |
Why?
| Presynaptic Terminals | 1 | 2011 | 55 | 0.100 |
Why?
| Excitatory Postsynaptic Potentials | 1 | 2011 | 101 | 0.090 |
Why?
| TOR Serine-Threonine Kinases | 1 | 2013 | 362 | 0.090 |
Why?
| Cell Survival | 4 | 2018 | 1024 | 0.090 |
Why?
| Mitogen-Activated Protein Kinase 9 | 1 | 2010 | 18 | 0.090 |
Why?
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2010 | 19 | 0.090 |
Why?
| Single-Chain Antibodies | 1 | 2010 | 14 | 0.090 |
Why?
| Rats | 5 | 2011 | 5034 | 0.090 |
Why?
| Pineal Gland | 1 | 2010 | 12 | 0.090 |
Why?
| Pinealoma | 1 | 2010 | 11 | 0.090 |
Why?
| Immunotherapy, Active | 1 | 2010 | 8 | 0.090 |
Why?
| Neurodegenerative Diseases | 1 | 2011 | 92 | 0.090 |
Why?
| Vaccines, Subunit | 1 | 2010 | 41 | 0.080 |
Why?
| Immunohistochemistry | 4 | 2019 | 1642 | 0.080 |
Why?
| Aged, 80 and over | 5 | 2020 | 6419 | 0.080 |
Why?
| Female | 12 | 2020 | 59932 | 0.080 |
Why?
| Magnetic Resonance Imaging | 2 | 2019 | 3071 | 0.080 |
Why?
| Reactive Oxygen Species | 2 | 2022 | 549 | 0.080 |
Why?
| Bevacizumab | 1 | 2010 | 118 | 0.080 |
Why?
| Cell Lineage | 1 | 2011 | 310 | 0.080 |
Why?
| Membrane Proteins | 1 | 2015 | 1024 | 0.080 |
Why?
| Mutation | 3 | 2013 | 3364 | 0.080 |
Why?
| Injections, Intraventricular | 2 | 2020 | 72 | 0.080 |
Why?
| Extracellular Matrix Proteins | 1 | 2010 | 127 | 0.080 |
Why?
| Down Syndrome | 1 | 2013 | 336 | 0.080 |
Why?
| Synapses | 1 | 2011 | 336 | 0.080 |
Why?
| Transcription, Genetic | 1 | 2014 | 1310 | 0.080 |
Why?
| Cell Transformation, Neoplastic | 1 | 2010 | 314 | 0.080 |
Why?
| Adaptation, Physiological | 1 | 2011 | 476 | 0.080 |
Why?
| Angiogenesis Inhibitors | 1 | 2010 | 216 | 0.080 |
Why?
| Antibodies, Blocking | 2 | 2018 | 32 | 0.080 |
Why?
| RNA, Messenger | 2 | 2012 | 2574 | 0.070 |
Why?
| Recombinant Proteins | 1 | 2010 | 1243 | 0.070 |
Why?
| Apoptosis | 3 | 2022 | 2377 | 0.070 |
Why?
| Transcriptome | 2 | 2023 | 736 | 0.070 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2010 | 503 | 0.070 |
Why?
| Male | 9 | 2020 | 55968 | 0.070 |
Why?
| Follow-Up Studies | 3 | 2020 | 4440 | 0.070 |
Why?
| Neoplasm Metastasis | 2 | 2018 | 526 | 0.060 |
Why?
| Cytoskeletal Proteins | 1 | 2006 | 145 | 0.060 |
Why?
| Carcinoma, Squamous Cell | 1 | 2010 | 577 | 0.060 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2010 | 667 | 0.060 |
Why?
| Combined Modality Therapy | 2 | 2019 | 1127 | 0.060 |
Why?
| Heterografts | 2 | 2016 | 119 | 0.060 |
Why?
| Receptors, AMPA | 1 | 2006 | 120 | 0.060 |
Why?
| Gene Expression | 2 | 2010 | 1436 | 0.060 |
Why?
| Infant, Newborn | 1 | 2015 | 5060 | 0.060 |
Why?
| Disease-Free Survival | 2 | 2017 | 621 | 0.060 |
Why?
| Neoplasm Transplantation | 2 | 2015 | 235 | 0.060 |
Why?
| Survival Rate | 2 | 2019 | 1650 | 0.060 |
Why?
| Neuronal Plasticity | 1 | 2006 | 214 | 0.060 |
Why?
| Flow Cytometry | 3 | 2012 | 1083 | 0.060 |
Why?
| Gene Dosage | 2 | 2013 | 129 | 0.050 |
Why?
| Blotting, Western | 3 | 2012 | 1153 | 0.050 |
Why?
| Aged | 5 | 2020 | 19255 | 0.050 |
Why?
| Carcinoma, Non-Small-Cell Lung | 1 | 2010 | 963 | 0.050 |
Why?
| Radiation, Ionizing | 1 | 2022 | 73 | 0.050 |
Why?
| Cell Respiration | 1 | 2022 | 74 | 0.050 |
Why?
| Electron Transport | 1 | 2022 | 112 | 0.050 |
Why?
| Electrons | 1 | 2022 | 72 | 0.050 |
Why?
| Epithelial-Mesenchymal Transition | 1 | 2023 | 167 | 0.050 |
Why?
| NAD | 1 | 2022 | 67 | 0.050 |
Why?
| Time Factors | 3 | 2019 | 6165 | 0.050 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2022 | 214 | 0.050 |
Why?
| Cell Separation | 2 | 2013 | 293 | 0.050 |
Why?
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2022 | 171 | 0.050 |
Why?
| Drosophila | 1 | 2022 | 132 | 0.050 |
Why?
| Tumor Cells, Cultured | 2 | 2013 | 850 | 0.050 |
Why?
| In Situ Hybridization, Fluorescence | 2 | 2012 | 310 | 0.040 |
Why?
| Treatment Outcome | 3 | 2019 | 9159 | 0.040 |
Why?
| Indazoles | 1 | 2020 | 58 | 0.040 |
Why?
| Maximum Tolerated Dose | 1 | 2020 | 182 | 0.040 |
Why?
| Pyrazines | 1 | 2020 | 70 | 0.040 |
Why?
| Tissue Distribution | 1 | 2020 | 324 | 0.040 |
Why?
| Medical Oncology | 1 | 2021 | 230 | 0.040 |
Why?
| Epitopes | 2 | 2011 | 438 | 0.040 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2012 | 930 | 0.040 |
Why?
| Twist-Related Protein 1 | 1 | 2018 | 10 | 0.040 |
Why?
| Sulfonamides | 1 | 2022 | 447 | 0.040 |
Why?
| Europe | 1 | 2019 | 336 | 0.040 |
Why?
| Parabiosis | 1 | 2018 | 12 | 0.040 |
Why?
| Chromosomes, Human, Pair 10 | 1 | 2018 | 18 | 0.040 |
Why?
| Particle Size | 1 | 2019 | 319 | 0.040 |
Why?
| Surface Properties | 1 | 2019 | 397 | 0.040 |
Why?
| Lung Neoplasms | 1 | 2010 | 2207 | 0.040 |
Why?
| Chemokine CCL2 | 1 | 2018 | 105 | 0.040 |
Why?
| Middle Aged | 4 | 2020 | 27014 | 0.040 |
Why?
| Mice, Nude | 1 | 2019 | 639 | 0.040 |
Why?
| Allografts | 1 | 2018 | 127 | 0.040 |
Why?
| Rats, Nude | 1 | 2017 | 27 | 0.040 |
Why?
| Immunocompetence | 1 | 2017 | 41 | 0.040 |
Why?
| Drug Administration Schedule | 1 | 2019 | 724 | 0.040 |
Why?
| Animals, Newborn | 2 | 2011 | 780 | 0.040 |
Why?
| Recurrence | 1 | 2019 | 952 | 0.030 |
Why?
| Fetus | 1 | 2020 | 702 | 0.030 |
Why?
| Monocytes | 1 | 2019 | 507 | 0.030 |
Why?
| Child | 3 | 2020 | 18487 | 0.030 |
Why?
| Up-Regulation | 1 | 2018 | 820 | 0.030 |
Why?
| Receptors, Antigen, T-Cell | 1 | 2019 | 630 | 0.030 |
Why?
| Phenazines | 1 | 2014 | 9 | 0.030 |
Why?
| Models, Biological | 2 | 2017 | 1646 | 0.030 |
Why?
| Double-Blind Method | 1 | 2019 | 1659 | 0.030 |
Why?
| Naphthyridines | 1 | 2014 | 16 | 0.030 |
Why?
| Zinc Finger Protein Gli2 | 1 | 2014 | 3 | 0.030 |
Why?
| Zinc Finger Protein GLI1 | 1 | 2014 | 21 | 0.030 |
Why?
| AC133 Antigen | 1 | 2013 | 20 | 0.030 |
Why?
| G1 Phase Cell Cycle Checkpoints | 1 | 2013 | 8 | 0.030 |
Why?
| Kruppel-Like Transcription Factors | 1 | 2014 | 61 | 0.030 |
Why?
| Inflammation Mediators | 1 | 2017 | 479 | 0.030 |
Why?
| Mice, Transgenic | 1 | 2019 | 1970 | 0.030 |
Why?
| Chromosomes, Human, Pair 21 | 1 | 2013 | 31 | 0.030 |
Why?
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2013 | 57 | 0.030 |
Why?
| Benzimidazoles | 1 | 2014 | 137 | 0.030 |
Why?
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2013 | 58 | 0.030 |
Why?
| Antibodies, Bispecific | 1 | 2013 | 33 | 0.030 |
Why?
| Gene Amplification | 1 | 2013 | 96 | 0.030 |
Why?
| Microscopy, Electron, Transmission | 1 | 2013 | 138 | 0.030 |
Why?
| Spheroids, Cellular | 1 | 2013 | 57 | 0.030 |
Why?
| Adult Stem Cells | 1 | 2013 | 32 | 0.030 |
Why?
| Ubiquitination | 1 | 2013 | 86 | 0.030 |
Why?
| Kaplan-Meier Estimate | 1 | 2015 | 815 | 0.030 |
Why?
| Trisomy | 1 | 2013 | 68 | 0.030 |
Why?
| Child, Preschool | 2 | 2020 | 9131 | 0.030 |
Why?
| Mammary Glands, Animal | 1 | 2013 | 116 | 0.030 |
Why?
| beta Catenin | 1 | 2014 | 220 | 0.030 |
Why?
| Immunoconjugates | 1 | 2013 | 87 | 0.030 |
Why?
| Antihypertensive Agents | 1 | 2016 | 432 | 0.030 |
Why?
| Epithelium | 1 | 2013 | 297 | 0.030 |
Why?
| Ligands | 1 | 2014 | 569 | 0.030 |
Why?
| Mice, Knockout | 1 | 2018 | 2604 | 0.030 |
Why?
| Colorado | 1 | 2022 | 4116 | 0.030 |
Why?
| Cellular Senescence | 1 | 2013 | 153 | 0.030 |
Why?
| Cyclin-Dependent Kinase 5 | 1 | 2011 | 3 | 0.030 |
Why?
| Disease Progression | 1 | 2019 | 2418 | 0.030 |
Why?
| Drosophila melanogaster | 1 | 2013 | 190 | 0.030 |
Why?
| Colforsin | 1 | 2011 | 46 | 0.030 |
Why?
| Glycoproteins | 1 | 2013 | 309 | 0.020 |
Why?
| RNA Interference | 1 | 2013 | 438 | 0.020 |
Why?
| Tetrodotoxin | 1 | 2011 | 40 | 0.020 |
Why?
| Trinucleotide Repeat Expansion | 1 | 2011 | 24 | 0.020 |
Why?
| Biophysical Phenomena | 1 | 2011 | 63 | 0.020 |
Why?
| Immunoenzyme Techniques | 1 | 2012 | 193 | 0.020 |
Why?
| Feedback, Physiological | 1 | 2011 | 73 | 0.020 |
Why?
| Organ Culture Techniques | 1 | 2011 | 143 | 0.020 |
Why?
| Nerve Fibers | 1 | 2011 | 87 | 0.020 |
Why?
| Molecular Weight | 1 | 2011 | 329 | 0.020 |
Why?
| Antigens, CD | 1 | 2013 | 442 | 0.020 |
Why?
| Cell Aggregation | 1 | 2011 | 24 | 0.020 |
Why?
| Oligodendrocyte Transcription Factor 2 | 1 | 2011 | 18 | 0.020 |
Why?
| Nestin | 1 | 2011 | 17 | 0.020 |
Why?
| Anesthetics, Local | 1 | 2011 | 84 | 0.020 |
Why?
| Amino Acid Sequence | 1 | 2015 | 2000 | 0.020 |
Why?
| Patch-Clamp Techniques | 1 | 2011 | 245 | 0.020 |
Why?
| Electric Stimulation | 1 | 2011 | 263 | 0.020 |
Why?
| Intermediate Filament Proteins | 1 | 2011 | 66 | 0.020 |
Why?
| Pons | 1 | 2011 | 30 | 0.020 |
Why?
| Antibody Affinity | 1 | 2010 | 52 | 0.020 |
Why?
| Nerve Degeneration | 1 | 2010 | 40 | 0.020 |
Why?
| Cross Reactions | 1 | 2010 | 117 | 0.020 |
Why?
| Hematopoietic Stem Cells | 1 | 2013 | 346 | 0.020 |
Why?
| Molecular Sequence Data | 1 | 2015 | 2790 | 0.020 |
Why?
| Cell Division | 1 | 2012 | 759 | 0.020 |
Why?
| Promoter Regions, Genetic | 1 | 2014 | 1122 | 0.020 |
Why?
| Cell Cycle Proteins | 1 | 2013 | 553 | 0.020 |
Why?
| Isoenzymes | 1 | 2010 | 285 | 0.020 |
Why?
| Mutagenesis, Site-Directed | 1 | 2010 | 346 | 0.020 |
Why?
| HEK293 Cells | 1 | 2011 | 602 | 0.020 |
Why?
| Drug Evaluation, Preclinical | 1 | 2010 | 166 | 0.020 |
Why?
| Cytokines | 1 | 2017 | 1853 | 0.020 |
Why?
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2011 | 225 | 0.020 |
Why?
| STAT3 Transcription Factor | 1 | 2010 | 174 | 0.020 |
Why?
| Nerve Net | 1 | 2011 | 228 | 0.020 |
Why?
| Protein Isoforms | 1 | 2010 | 339 | 0.020 |
Why?
| Fibroblasts | 1 | 2013 | 839 | 0.020 |
Why?
| RNA, Small Interfering | 1 | 2010 | 544 | 0.020 |
Why?
| Phenotype | 1 | 2016 | 2831 | 0.020 |
Why?
| Peptide Fragments | 1 | 2012 | 675 | 0.020 |
Why?
| Regression Analysis | 1 | 2010 | 959 | 0.020 |
Why?
| Mice, Inbred C57BL | 1 | 2017 | 4773 | 0.020 |
Why?
| Biomarkers, Tumor | 1 | 2013 | 1048 | 0.020 |
Why?
| Hippocampus | 1 | 2011 | 709 | 0.020 |
Why?
| Infant | 1 | 2020 | 7976 | 0.020 |
Why?
| Rats, Sprague-Dawley | 1 | 2011 | 2262 | 0.020 |
Why?
| Bicuculline | 1 | 2006 | 21 | 0.020 |
Why?
| GABA Antagonists | 1 | 2006 | 32 | 0.020 |
Why?
| Blotting, Northern | 1 | 2006 | 194 | 0.020 |
Why?
| Excitatory Amino Acid Antagonists | 1 | 2006 | 89 | 0.020 |
Why?
| In Situ Hybridization | 1 | 2006 | 298 | 0.020 |
Why?
| Brain-Derived Neurotrophic Factor | 1 | 2006 | 106 | 0.020 |
Why?
| Clinical Trials as Topic | 1 | 2010 | 941 | 0.020 |
Why?
| Adult | 2 | 2020 | 30726 | 0.020 |
Why?
| Drug Interactions | 1 | 2006 | 347 | 0.020 |
Why?
| Adolescent | 2 | 2015 | 17903 | 0.020 |
Why?
| Neostriatum | 1 | 2004 | 29 | 0.010 |
Why?
| In Vitro Techniques | 1 | 2006 | 1044 | 0.010 |
Why?
| Transfection | 1 | 2006 | 866 | 0.010 |
Why?
| Cerebral Cortex | 1 | 2006 | 386 | 0.010 |
Why?
| United States | 1 | 2019 | 12297 | 0.010 |
Why?
| Enzyme Inhibitors | 1 | 2006 | 757 | 0.010 |
Why?
| Vaccination | 1 | 2010 | 1210 | 0.010 |
Why?
| Calcium | 1 | 2006 | 1103 | 0.010 |
Why?
| Cell Line | 1 | 2004 | 2651 | 0.010 |
Why?
| Lung | 1 | 2010 | 3673 | 0.010 |
Why?
|
|
Mitra's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|